Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.67 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.67 |
| ▸ | MAOB | P27338 | 2/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 9/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorosalan SCHEMBL30318966 | 1.00 | MEN1 (1.00) | MEN1HTTKMT2AOPRK1HSPD1 | |
| Fluorosalan SCHEMBL374268 | 1.00 | MEN1 (1.00) | MEN1HTTKMT2AOPRK1HSPD1 | |
| Fluorosalan SCHEMBL30288529 | 1.00 | MEN1 (1.00) | MEN1HTTKMT2AOPRK1HSPD1 | |
| Fluorosalan SCHEMBL8668901 | 0.95 | MEN1 (0.91) | MEN1HTTKMT2AOPRK1HSPD1 | |
| SCHEMBL4922276 | 0.87 | MEN1 (0.76) | MEN1HTTKMT2AOPRK1HSPD1 | |
| SCHEMBL574776 | 0.85 | MEN1 (0.74) | MEN1HTTKMT2AOPRK1HSPD1 | |
| SCHEMBL331050 | 0.85 | MEN1 (0.74) | MEN1HTTKMT2AOPRK1HSPD1 | |
| SCHEMBL330388 | 0.83 | TMPRSS4 (0.78) | MEN1HTTKMT2AOPRK1P2RX1 | |
| SCHEMBL15209878 | 0.82 | MEN1 (0.70) | MEN1HTTKMT2AOPRK1MAOB | |
| Cetylpyridinium SCHEMBL11499480 | 0.82 | MEN1 (0.67) | MEN1HTTKMT2AOPRK1HSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528776-B1 | REDUCED-ETHANOL MOUTH RINSE FORMULATIONS | KENVUE BRANDS LLC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4551195-A1 | CANNABINOID LIPID PREMIXTURE | Fertin Pharma A/S (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025067622-A1 | CANNABIDIOL FOR USE IN ALLEVIATING XEROSTOMIA | FERTIN PHARMA A/S (DK) | 2025-04-03 | — | — | WO | disclosed |
| CN-119562805-A | Cannabinoid lipid premix | 费尔廷制药公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4088716-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2024-10-16 | — | — | EP | disclosed |
| CN-112153964-B | Oral tablets suitable for active pharmaceutical ingredient comprising non-directly compressible sugar alcohol particles | 费尔廷制药公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2024008261-A1 | CANNABINOID LIPID PREMIXTURE | FERTIN PHARMA A/S (DK) | 2024-01-11 | — | — | WO | disclosed |
| US-11857653-B2 | Method of providing an oral care benefit using a poorly-soluble calcium compound and fluoride | JOHNSON & JOHNSON CONSUMER INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-3787604-B1 | A TABLETED CHEWING GUM SUITABLE FOR ACTIVE PHARMACEUTICAL INGREDIENTS | FERTIN PHARMA AS (DK) | 2023-07-05 | — | — | EP | disclosed |
| US-11648186-B2 | Coated particles and their uses | JOHNSON & JOHNSON CONSUMER INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4088716-A1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | Fertin Pharma A/S (DK) | 2022-11-16 | — | — | EP | disclosed |
| US-20220331222-A1 | Method of Providing Oral Care Benefits | KENVUE BRANDS LLC | 2022-10-20 | — | — | US | disclosed |
| US-20220226205-A1 | Coated Particles and Their Uses | KENVUE BRANDS LLC | 2022-07-21 | — | — | US | disclosed |
| EP-3773511-B1 | AN ORAL TABLET FOR INDUCED SALIVA GENERATION | FERTIN PHARMA AS (DK) | 2022-07-06 | — | — | EP | disclosed |
| US-11351103-B2 | Method of providing oral care benefits | JOHNSON & JOHNSON CONSUMER INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11291613-B2 | Coated particles and their uses | JOHNSON & JOHNSON CONSUMER INC. (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291613-B2 | Coated particles and their uses | CD63, EPCAM, CD44 | MEN1 3074/4885HTT 1520/4885KMT2A 2405/4885 |
| US-11648186-B2 | Coated particles and their uses | CD63, EPCAM, CD44 | MEN1 3074/4885HTT 1520/4885KMT2A 2405/4885 |
| US-20220226205-A1 | Coated Particles and Their Uses | CD63, EPCAM, CD44 | MEN1 3074/4885HTT 1520/4885KMT2A 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.